Benitec Biopharma (BNTC) Cash from Investing Activities (2019 - 2025)

Benitec Biopharma has reported Cash from Investing Activities for 6 years, with the latest figure at -$11000.0 in Q4 2025.

• Quarterly Cash from Investing Activities changed N/A year-over-year to -$11000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$29000.0 (up 83.8% YoY) and the FY2025 annual result came in at -$18000.0, up 89.94% from the prior year.
• Cash from Investing Activities climbed to -$11000.0 in Q4 2025 per BNTC's latest filing, from -$18000.0 in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $141000.0 in Q2 2021 and troughed at -$179000.0 in Q1 2024.
• A 4-year average of -$15833.3 and a median of -$14000.0 in 2021 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2021 and 2022: Cash from Investing Activities jumped 1184.62% in 2021, then plunged 109.22% in 2022.
• Over 4 years, Cash from Investing Activities stood at $141000.0 in 2021, then slumped by 109.22% to -$13000.0 in 2022, then slumped by 1276.92% to -$179000.0 in 2024, then soared by 93.85% to -$11000.0 in 2025.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$11000.0, -$18000.0, and -$179000.0 for Q4 2025, Q2 2025, and Q1 2024 respectively.